All Title Author
Keywords Abstract

Escherichia coli Resistance to Ciprofloxacin in Acute Uncomplicated Pyelonephritis

DOI: 10.4236/oalib.1104043, PP. 1-6

Keywords: E. coli, Pyelonephritis, Ciprofloxacin

Full-Text   Cite this paper   Add to My Lib


Background: Severe acute uncomplicated pyelonephritis is an infection of the kidneys that usually have an ascending route and occur in presumably healthy urinary tract. The most common pathogen involved is E. coli. The Infectious Diseases Society of America (IDSA) has issued an updated guideline in 2010 suggesting IV quinolones to be considered in the initial empiric antimicrobial therapy giving known resistance of less than 10%. However, E. coli resistance to quinolones has been increasing, the recent data of E. coli, causing pyelonephritis, resistance is not known in the Midwest. Local hospital antibiogram for two years showed up to 22% resistance to ciprofloxacin among E. coli isolates. Methods: We conduct a retrospective non-concurrent cohort study in one teaching hospital in the Midwest, females who were admitted with severe acute uncomplicated pyelonephritis in a three years period were included. Patients with urinary tract obstruction, pregnancy, immuno-suppression, males, and indwelling Foley’s catheters were excluded. Data collected include causative pathogens and resistance to antibiotics were collected. Percentages, frequencies, and measures of central tendency and dispersion were calculated to describe the study sample Results: 73 patients were included in the final analysis. E. coli was the most common isolated pathogen (81%), followed by other enteric gram negative. E. coli resistance to ciprofloxacin was 13.5%, 37% to trimethoprim-sulfamethoxazole, and 5% to ceftriaxone. Conclusion: Ciprofloxacin should be avoided initially in treating severe acute uncomplicated pyelonephritis until culture results and sensitivity is available.


[1]  Czaja, C.A., Scholes, D., Hooton, T.M., et al. (2007) Population-Based Epidemiologic Analysis of Acute Pyelonephritis. Clinical Infectious Diseases, 45, 273-280.
[2]  Gupta, K., Hooton, T.M., Naber, K.G., et al. (2011) International Clinical Practice Guidelines for the Treatment of Acute Un-complicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases, 52, e103-e120.
[3]  Hooton, T.M. (2012) Uncomplicated Urinary Tract Infection. New England Journal of Medicine, 366, 1028-1037.
[4]  Zhanel, G., Hisanaga, T., Laing, N., et al. (2006) Antibiotic Resistance in Escherichia coli Outpatient Urinary Isolates: Final Results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). International Journal of Antimicrobial Agents, 27, 468-475.
[5]  Smith, S.C., Bazzoli, C., Chung, I., et al. (2015) Antimicrobial Susceptibility of Escherichia coli in Uncomplicated Cystitis in the Emergency Department: Is the Hospital Antibiogram an Effective Treatment Guide? In: Bogucki, S., Ed., Academic Emergency Medicine, 22, 998-1000.
[6]  Echols, R.M., Tosiello, R.L., Haver-stock, D.C., et al. (1999) Demographic, Clinical, and Treatment Parameters Influencing the Outcome of Acute Cystitis. Clinical Infectious Diseases, 29, 113-119.
[7]  Talan, D.A., Stamm, W.E., Hooton, T.M., et al. (2017) Comparison of Ciprofloxacin (7 Days) and Trimethoprimsulfamethoxazole (14 Days) for Acute Uncomplicated Pyelonephritis Pyelonephritis in Women: A Randomized Trial. JAMA, 283, 1583- 1590.
[8]  Hooper, D.C. (1999) Mechanisms of Fluoroquinolone Resistance. Drug Resistance Updates, 2, 38-55.
[9]  Martínez-Martínez, L., Pascual, A. and Jacoby, G.A. (1998) Quinolone Resistance from a Transferable Plasmid. Lancet (London, England), 351, 797-799.
[10]  Sanchez, G.V., Master, R.N., Karlowsky, J.A., et al. In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010. Antimicrobial Agents and Chemotherapy, 56, 2181-2183.


comments powered by Disqus